Elsewhere, it has been shown that SMAD has a prognostic value in GC patients; meanwhile, CTNNB1 mutations have decreased expression of βcatenin, which is associated with poor tumor differentiation and shorter overall survival [26]. This evidence concerns the gene CTNNB1 and gastric cancer.